Despite Years of Development, Affymetrix's Dx Partners Slow to Bring Tests to Market

Skyline Diagnostics' AMLprofiler leukemia test recently became the fourth Affy-based test to hit the market. Some of the company's other diagnostic partners, however, have changed their development strategies since the "Powered by Affymetrix" program was launched.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.